| Dr Ilana Lindsay Forchheimer, MD | |
|
329 E Main St, Suite 10, Smithtown, NY 11787-2830 | |
| (631) 265-2580 | |
| Not Available |
| Full Name | Dr Ilana Lindsay Forchheimer |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 16 Years |
| Location | 329 E Main St, Smithtown, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720242514 | NPI | - | NPPES |
| 255460 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 255460 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore - Lij Medical Pc | 3375701568 | 5099 |
News Archive
Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.
After all the posturing and grand standing the states have finally reached a compromise on the financial healthcare reforms suggested by the Federal Government. Prime Misnter Kevin Rudd may be happy about the outcome, but he still has more to do. The work is only just beginning for the long haul.
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.
› Verified 3 days ago
| Entity Name | Prohealth Care Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275596280 PECOS PAC ID: 4486544186 Enrollment ID: O20040317000468 |
News Archive
Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.
After all the posturing and grand standing the states have finally reached a compromise on the financial healthcare reforms suggested by the Federal Government. Prime Misnter Kevin Rudd may be happy about the outcome, but he still has more to do. The work is only just beginning for the long haul.
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.
› Verified 3 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.
After all the posturing and grand standing the states have finally reached a compromise on the financial healthcare reforms suggested by the Federal Government. Prime Misnter Kevin Rudd may be happy about the outcome, but he still has more to do. The work is only just beginning for the long haul.
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ilana Lindsay Forchheimer, MD 329 E Main St, Suite 10, Smithtown, NY 11787-2830 Ph: (631) 265-2580 | Dr Ilana Lindsay Forchheimer, MD 329 E Main St, Suite 10, Smithtown, NY 11787-2830 Ph: (631) 265-2580 |
News Archive
Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.
After all the posturing and grand standing the states have finally reached a compromise on the financial healthcare reforms suggested by the Federal Government. Prime Misnter Kevin Rudd may be happy about the outcome, but he still has more to do. The work is only just beginning for the long haul.
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.
› Verified 3 days ago
Dr. Michelle Liebert, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 260 E Middle Country Rd, Suite 201, Smithtown, NY 11787 Phone: 631-265-8780 | |
Dr. John Mauro, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 260 E Middle Country Rd, Suite 201, Smithtown, NY 11787 Phone: 631-265-8780 | |
Jeffrey L Martin, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 260 Middle Country Rd, Suite 201, Smithtown, NY 11787 Phone: 631-265-8780 | |
Dr. Robert Peter Morris, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 222 E Main St, Suite 330, Smithtown, NY 11787 Phone: 631-724-4488 Fax: 631-366-0958 | |
Mr. Andrew N. Bainnson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 260 E Middle Country Rd, Suite 201, Smithtown, NY 11787 Phone: 631-265-8780 Fax: 631-265-8521 | |
Dr. Faye Knoll, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 260 E Middle Country Rd, Suite 201, Smithtown, NY 11787 Phone: 631-265-8780 Fax: 631-265-8521 |